GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microlin Bio Inc (GREY:MICB) » Definitions » LT-Debt-to-Total-Asset

Microlin Bio (Microlin Bio) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2015)


View and export this data going back to 2014. Start your Free Trial

What is Microlin Bio LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Microlin Bio's long-term debt to total assests ratio for the quarter that ended in Sep. 2015 was 0.00.

Microlin Bio's long-term debt to total assets ratio stayed the same from Sep. 2014 (0.00) to Sep. 2015 (0.00).


Microlin Bio LT-Debt-to-Total-Asset Historical Data

The historical data trend for Microlin Bio's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microlin Bio LT-Debt-to-Total-Asset Chart

Microlin Bio Annual Data
Trend Dec12 Dec13 Dec14
LT-Debt-to-Total-Asset
- - -

Microlin Bio Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Microlin Bio LT-Debt-to-Total-Asset Calculation

Microlin Bio's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2014 is calculated as

LT Debt to Total Assets (A: Dec. 2014 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2014 )/Total Assets (A: Dec. 2014 )
=0/0.003
=0.00

Microlin Bio's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2015 is calculated as

LT Debt to Total Assets (Q: Sep. 2015 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2015 )/Total Assets (Q: Sep. 2015 )
=0/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microlin Bio  (GREY:MICB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Microlin Bio LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Microlin Bio's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Microlin Bio (Microlin Bio) Business Description

Traded in Other Exchanges
N/A
Address
MicroLin Bio Inc is engaged in the healthcare sector. It is a therapeutic and diagnostic company focusing on microRNA and its role in oncology. MicroRNAs represent a class of diagnostics and therapeutics that are more effective in the diagnosis and treatment of cancer, with the potential for mitigating side effects in comparison with conventional small molecule drugs or biologics. The company's properties include molecular diagnostics and companion tests, cancer therapeutics, and delivery platform technology. Molecular diagnostics & companion tests include tests such as Lumira, Omira, Colomira, and Promira. Cancer therapeutics includes lumiralin, omiralin, colomiralin, and promirali.

Microlin Bio (Microlin Bio) Headlines

No Headlines